Results 241 to 250 of about 17,532 (272)

Nanostructures in non-invasive prenatal genetic screening

Biomedical Engineering Letters, 2021
Prenatal screening is an important issue during pregnancy to ensure fetal and maternal health, as well as preventing the birth of a defective fetus and further problems such as extra costs for the family and society. The methods for the screening have progressed to non-invasive approaches over the recent years.
Samira Sadeghi
exaly   +3 more sources

Non-invasive prenatal screening for trisomy 21: What women want and are willing to pay

Patient Education and Counseling, 2013
To investigate the attitude among pregnant women regarding non-invasive prenatal testing (NIPT) for detecting trisomy 21 (T21) and to quantify their willingness to pay for NIPT.A questionnaire was administered to pregnant women who received counselling for first-trimester screening (FTS) in two hospitals and nine midwife practices in the Netherlands.A ...
Dick Oepkes, Marieke De Vries, Marjon A De Boer   +2 more
exaly   +4 more sources

Experiences of non‐invasive prenatal screening: A survey study

Australian and New Zealand Journal of Obstetrics and Gynaecology, 2021
Background:In Australia, using non‐invasive prenatal testing (NIPT) to screen for fetal abnormalities is becoming more commonplace. However, there is a lack of standardised procedures surrounding pre‐test counselling. This holds the potential for variability in pregnant people’s experiences when undergoing NIPT, which subsequently may impact their ...
Paige Cornell, Taylah Armstrong, Rina Fyfe, Carly A. Mallise, Tracy Dudding‐Byth, Linda E. Campbell   +5 more
openaire   +2 more sources

Diagnostic performance and costs of contingent screening models for trisomy 21 incorporating non‐invasive prenatal testing

Australian and New Zealand Journal of Obstetrics and Gynaecology, 2017
© 2017 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists Background: Contingent screening for trisomy 21 using non-invasive prenatal testing has the potential to reduce invasive diagnostic testing and increase the detection
Susannah Maxwell, Jan E Dickinson
exaly   +2 more sources

Non-invasive prenatal diagnosis and screening for monogenic disorders

European Journal of Obstetrics & Gynecology and Reproductive Biology, 2020
Cell-free fetal DNA (cffDNA) can be detected in the maternal circulation from 4 weeks gestation, and is present with cell-free maternal DNA at a level of between 5 % and 20 %. Cell-free DNA (cfDNA) can be extracted from a maternal blood sample and, although it is not possible to separate the fetal from the maternal cfDNA, it has enabled non-invasive ...
E, Scotchman, J, Shaw, B, Paternoster, N, Chandler, L S, Chitty   +4 more
openaire   +2 more sources

Non-Invasive Prenatal Screening: Navigating the Relevant Legal Norms

Journal of Obstetrics and Gynaecology Canada, 2020
The implementation of non-invasive prenatal screening (NIPS) in Canada will be affected by legal norms. The law can shape physician behaviour, help to crystallize standards of care, influence utilization patterns, and reflect and reinforce patient expectations.
Blake, Murdoch, Timothy, Caulfield
openaire   +2 more sources

Non-invasive prenatal screening for foetal trisomy: An assessment of reliability and reporting

Clinical Biochemistry, 2022
Non-invasive prenatal screening (NIPS) has been introduced as a routine screening technique for aneuploidies in the clinic. To evaluate its reliability and reporting standardization, the National Center for Clinical Laboratories launched an external quality assessment (EQA) program based on highly simulated samples.Maternal and child paired cell lines ...
Jiping, Shi, Ping, Tan, Dongsheng, Han, Runling, Zhang, Jinming, Li, Rui, Zhang   +5 more
openaire   +2 more sources

Expanding the scope of non-invasive prenatal screening

Nature Genetics
Non-invasive prenatal screening has swiftly been implemented as a first- or second-tier test for common fetal aneuploidies and typically relies on sequencing maternal circulating cell-free DNA (cfDNA). This cfDNA comprises both the maternal and fetal genomes and the epigenetic features of its cells of origin.
Kate Elizabeth Stanley, Bernard Thienpont, Joris Robert Vermeesch   +2 more
openaire   +2 more sources

Prenatal screening and non-invasive prenatal testing regulation in the Russian Federation

Voprosy ginekologii, akušerstva i perinatologii, 2020
Congenital malformations, chromosomal and monogenic disease play a significant role in perinatal mortality and child disability. According to the early prenatal screening results in the Russian Federation in 2018, the overall ratio of chromosomal anomaly prevalence is 1:250–1:300.
A.S. Olenev, E.E. Baranova, O.V. Sagaydak, A.M. Galaktionova, M.S. Belenikin, V.A. Gnetetskaya, G.Yu. Zobkova, E.V. Kosova, M.V. Makarova, E.N. Songolova   +9 more
openaire   +1 more source

Non‐invasive prenatal screening for trisomy 21: Consumers' perspectives

American Journal of Medical Genetics Part A, 2015
Non‐invasive prenatal screening (NIPS) has the potential to dramatically increase the prenatal detection rate of Down syndrome because of improvements in safety and accuracy over existing tests. There is concern that NIPS could lead to more negative attitudes towards Down syndrome and less support for individuals with Down syndrome.
Emily C, Higuchi, Jane P, Sheldon, Brian J, Zikmund-Fisher, Beverly M, Yashar   +3 more
openaire   +2 more sources